Evidence map›Paper›PMID 41280508›Full record

ArticleInternational journal of pharmaceutics: X2025

Inhalative polyclonal immunoglobulin G for the prevention of respiratory infections: A comprehensive

Rebecca Rittersberger, Caroline Covini, Shruthi Kalgudde, Pramod Kumar, Franziska Voß, Janik Martin, Franziska Magdalena Deuter, Gabriel Koslowski, Annabelle Dabbars, Sophia Salcher and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of pharmaceutics: X, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Rebecca RittersbergerInstitute of Applied Biotechnology, Biberach University of Applied Science, Hubertus Liebrecht Strasse 35-39, 88400 Biberach, Germany.
Caroline CoviniOctapharma Pharmazeutika Produktionsgesellschaft mbH, Oberlaaerstrasse 235, 1100 Vienna, Austria.
Shruthi KalguddeInstitute of Lung Health and Immunity (LHI), Helmholtz Munich, Comprehensive Pneumology Center (CPC-M), Member of the German Center for Lung Research (DZL), Ingolstädter Landstraße 1, 85764 Neuherberg, Germany.
Pramod KumarInstitute of Lung Health and Immunity (LHI), Helmholtz Munich, Comprehensive Pneumology Center (CPC-M), Member of the German Center for Lung Research (DZL), Ingolstädter Landstraße 1, 85764 Neuherberg, Germany.
Franziska VoßDepartment of Molecular Genetics and Infection Biology, Interfaculty Institute for Ge- netics and Functional Genomics, Center for Functional Genomics of Microbes, University of Greifswald, Greifswald, Felix-Hausdorff-Str. 8, 17487 Greifswald, Germany.
Janik MartinInstitute of Applied Biotechnology, Biberach University of Applied Science, Hubertus Liebrecht Strasse 35-39, 88400 Biberach, Germany.
Franziska Magdalena DeuterInstitute of Applied Biotechnology, Biberach University of Applied Science, Hubertus Liebrecht Strasse 35-39, 88400 Biberach, Germany.
Gabriel KoslowskiInstitute of Applied Biotechnology, Biberach University of Applied Science, Hubertus Liebrecht Strasse 35-39, 88400 Biberach, Germany.
Annabelle DabbarsInstitute of Applied Biotechnology, Biberach University of Applied Science, Hubertus Liebrecht Strasse 35-39, 88400 Biberach, Germany.
Sophia SalcherInstitute of Applied Biotechnology, Biberach University of Applied Science, Hubertus Liebrecht Strasse 35-39, 88400 Biberach, Germany.
Marion BlayacInstitute of Lung Health and Immunity (LHI), Helmholtz Munich, Comprehensive Pneumology Center (CPC-M), Member of the German Center for Lung Research (DZL), Ingolstädter Landstraße 1, 85764 Neuherberg, Germany.
Jürgen RömischOctapharma Pharmazeutika Produktionsgesellschaft mbH, Oberlaaerstrasse 235, 1100 Vienna, Austria.
Andrej MurányiOctapharma Pharmazeutika Produktionsgesellschaft mbH, Oberlaaerstrasse 235, 1100 Vienna, Austria.
Jonas KnochPARI Pharma GmbH, Moosstrasse 3, 82319 Starnberg, Germany.
Ali Önder YildirimInstitute of Lung Health and Immunity (LHI), Helmholtz Munich, Comprehensive Pneumology Center (CPC-M), Member of the German Center for Lung Research (DZL), Ingolstädter Landstraße 1, 85764 Neuherberg, Germany.
Thomas M ConlonInstitute of Lung Health and Immunity (LHI), Helmholtz Munich, Comprehensive Pneumology Center (CPC-M), Member of the German Center for Lung Research (DZL), Ingolstädter Landstraße 1, 85764 Neuherberg, Germany.
Otmar SchmidInstitute of Lung Health and Immunity (LHI), Helmholtz Munich, Comprehensive Pneumology Center (CPC-M), Member of the German Center for Lung Research (DZL), Ingolstädter Landstraße 1, 85764 Neuherberg, Germany.
Sven HammerschmidtDepartment of Molecular Genetics and Infection Biology, Interfaculty Institute for Ge- netics and Functional Genomics, Center for Functional Genomics of Microbes, University of Greifswald, Greifswald, Felix-Hausdorff-Str. 8, 17487 Greifswald, Germany.
Katharina SchindowskiInstitute of Applied Biotechnology, Biberach University of Applied Science, Hubertus Liebrecht Strasse 35-39, 88400 Biberach, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inhalation therapy represents a promising strategy for the delivery of biopharmaceuticals for the local treatment of respiratory diseases. Purified polyclonal serum immunoglobulin G (IgG), also known as IVIg products, exhibit a solid reactivity against common viral and bacterial antigens. However, IVIg are usually delivered intravenously or subcutaneously, thus, not at the sites where most infections originate. Accordingly, a respiratory mucosal delivery of IVIg may have the potential to prevent infections at the mucosal barrier. To evaluate the feasibility and efficacy of inhalable IVIg for the prevention and therapy of respiratory infections, this study examined nebulization and its impact on protein quality, as well as potential effects on

Indexed as

BiopharmaceuticsFcRnIgGProtein formulationQualityToxicityVibrating mesh nebulizer

Identifiers

PMID41280508
PMCPMC12634831

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.